Bravo Multinational, Inc. Appoints Four New Members to “Business Advisory” Board

VIRGINIA BEACH, Va.–Bravo Multinational Incorporated (“Bravo Multinational” or the “Company”) (OTC: BRVO) announced the appointment of Mr. Mark Greenberg, Mr. Neil Davis, Mr. Stephen Scheffer and Mr. Edward Pergjini to the newly formed “Business Advisory” board, effective November 30, 2020. All four individuals have accepted their “Business Advisory” board seat positions.

Bravo Multinational created the “Business Advisory” board to assist the Company’s management and Board of Directors with the evaluation of business opportunities within the media, entertainment and sports industries as well as the electric metals and green alternative energy sectors. Each of the seated members has extensive experiences in these industries.

The Company filed a Form 8-K on December 1, 2020 with the United States Securities and Exchange Commission regarding the newly form “Business Advisory” board and its members.

Bios for the “Business Advisory” board members are below:

Mark Greenberg is the CEO of SEVN Sports Inc. He served as the Founder and Chief Executive Officer of EPIX from 2009 to 2017. As an early visionary in the video streaming industry, Mr. Greenberg led EPIX to become the first cross platform network and his work has influenced future streaming services including Netflix, Amazon and Hulu. Mr. Greenberg previously served as Executive Vice President for Showtime Networks, Inc., and Director of Direct Marketing at HBO (Home Box Office). Mr. Greenberg received his undergraduate degree from Providence College and his MBA from Columbia University.

Neil Davis is the Chief Business Development Officer of SEVN Sports Inc. Mr. Davis is a seasoned digital executive for various companies including, AOL, Blockbuster, Dish Network and Qello Media, where he served as Chief Business Officer. He was previously CEO at Monetize, where he consulted for the media and entertainment industries. Prior to that, he was Head of Corporate and Digital Development at Blockbuster-Dish Digital. Mr. Davis received his undergraduate degree from Arizona State University.

Stephen Scheffer has served almost 30 years at HBO (Home Box Office) as President of Film Programming, Video and Enterprises. Mr. Scheffer was responsible for overseeing all motion picture programming for HBO. As President of HBO Pictures, he was responsible for the financing and production of HBO’s Silver Screen Partners and Cinema Plus theatrical movie ventures. Prior to HBO, Mr. Scheffer held executive positions at Time Life Films, Allied Artists, Polydor Records, MGM and Columbia Pictures. Mr. Scheffer received his undergraduate degree from the United States Naval Academy in Annapolis, Maryland and his MBA from Harvard Business School.

Edward Pergjini is the President of Element Sports Group Inc, a wholly-owned subsidiary of Element Global, Inc. (OTC: ELGL) Mr. Pergjini has over 30-years of experience working with multinational companies across disciplines including, commercial strategy, team management, the construction and development of international brands, and the management of broad real estate heritages. He also has a strong understanding of cross-cultural marketing, along with deep expertise in the economic and financial workings of professional European soccer clubs. Mr. Pergjini resides in France and received his MBA from Fairleigh Dickinson University.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters disclosed at www.otcmarkets.com. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements

Bravo Multinational Inc Elects Three New Members to Board of Directors

VIRGINIA BEACH, Va.—Bravo Multinational Incorporated (“Bravo Multinational” or the “Company”) (OTC: BRVO) announced that it elected Mr. John LaViolette, Mr. Steven Gagnon and Mr. Sasha Shapiro to its board of directors, effective November 27, 2020.

All three individuals have accepted their Board seats and with their election, the Company’s Boardnow has five seated directors which still includes Mr. Merle Ferguson, Chairman since 2018, and Mr. Richard Kaiser, Director since 2015.

The Company filed a Form 8-K on November 27, 2020 with the Securities and Exchange Commission regarding these newly elected directors.

Bios for the new directors joining the Company’s Board of Director’s are below:

Mr. LaViolette is the Co-Founder and Co-CEO of Element International Inc, and Co-CEO and Director of Element Global, Inc. (OTC: ELGL). Mr. LaViolette was also a senior partner in the entertainment law firm of Bloom, Hergott, Diemer, Rosenthal, LaViolette, Feldman, Schenkman & Goodman LLP. He has deep relationships with all major Hollywood studios and networks and has represented a vast number of “A-list” actors, writers, and directors.

Mr. Gagnon is the Co-Founder and Co-CEO of Element International Inc., and Co-CEO and COO of Element Global, Inc. (OTC: ELGL). Mr. Gagnon has a 20-year history in media in the financing and production of film, television and music videos. Mr. Gagnon served as President of the sports group of Madison Sports and Entertainment Group, Inc., and worked as a supervisor in the offshore oil and construction industry for International Underwater Contractors.

Mr. Shapiro is President and Director of Element Global, Inc. (OTC: ELGL) and Vice Chairman and President of Element Media Group. Mr. Shapiro is Managing Director of Media Content Capital, a private equity fund focused on investments in early/medium-stage media, internet, and entertainment companies and he sits on the Board of Directors of Sonifi Solutions, QED International, Covert Media and VR MediaTech.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters disclosed at www.otcmarkets.com. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Element Media Group, Inc. Announces Acquisition of OTRO Studios

OTRO Studios Renamed Element Studios UK Upon Closing

LOS ANGELES – Element Global, Inc. (OTC: ELGL)(“Element Global”), a diversified holding Company, announced that its wholly-owned subsidiary, Element Media Group, Inc., acquired OTRO Studios, a premium production studio that creates content in partnership with talent from the world of sport and beyond, effective September 9, 2020. The renaming of OTRO Studios to Element Studios UK occurred at the close of this transaction.

 John LaViolette, Co-CEO of Element Global said, “Element Studios UK has a unique opportunity to become the go-to studio for sports entertainment programming for both talent and buyers. In addition, we see meaningful synergies and opportunities to accelerate the company’s growth. We are also very excited to be able to work with and support newly appointed CEO Claire McArdle and their top-tier, multi award-winning management team. We look forward to being able to tap into their wealth of international programming, content and production experience.”

 “We are thrilled to be a part of the Element Media Group team,” said Claire McArdle, Element Studios UK’s Chief Executive Officer. “We believe that this is a great outcome and will position us for significant future growth. The Element team really understands our vision for the future and will help us bring sports programming alive through the lens of entertainment.”

 About Element Global, Inc.

 Element Global, Inc (OTC: ELGL), a diversified holding Company with global business interests centered on media and production, distribution and streaming in original and licensed film and tv content globally. With acquisition targets and developing sports franchise, sports distribution, emerging technology, renewable energy, and mining and processing of electric base metals, the Company brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, supporting emissions reductions through the electrification of power, transport, industry and buildings, ELGL’s visions itself to capitalize on the increases in demand in these industries, www.elementglobal.com.

 About Element Studios UK

 Element Studios UK is a premium production studio that creates content in partnership with talent from the world of sport and beyond. The multi-award-winning team behind Element Studios UK brings decades of experience in sports, entertainment, music, comedy, and factual across premium long form, short and mid form, social platforms, as well as live and experiential events. The company has unprecedented access to top talent and industry contacts, coupled with a strong track record of delivering internationally.

 Safe Harbor Statement

 Under the Private Securities Litigation Reform Act of 1995, certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

 View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005488/en/

Element Sports Group, Inc. (ELGL) Announces Appointment of Edward Pergjini As President

Industry Veteran Brings Track Record of Value Creation and Proven Expertise In Sports Industry

Element Sports Group, Inc., a wholly-owned division of Element Global, Inc., (OTC: ELGL) announces the appointment of Edward Pergjini as President, effective June 2, 2020. Mr. Pergjini will be responsible for executing on the Company’s strategic mandate, which is focused on acquiring professional soccer clubs (in Europe known as football clubs), as well as, sports distribution companies globally.


“I am delighted to welcome Edward as President of Element Sports Group,” said Co-Founder and Co-CEO of Element Sports Group, Inc., John LaViolette. “In Edward, we have a proven leader with significant years of operating experience, and deep relationships in the professional European soccer industry as well as the broader sports sector globally. Fluent in six languages, Mr. Pergjini is a true global executive, and we believe he is the ideal candidate to lead the Company forward to fulfill its strategic vision of becoming a competitive leader in the global sports industry.”


“I am honored to be stepping into the role of President and to have the opportunity to work with a dynamic management team committed to building a world class, sports driven, organization,” said Incoming President, Edward Pergjini.


Mr. Pergjini joins Element with over 30-years of experience working with multinational companies across disciplines including, commercial strategy, team management, the construction and development of international brands, and the management of broad real estate heritages. He also has a strong understanding of cross-cultural marketing along with deep expertise in the economic and financial workings of professional European soccer clubs. Mr. Pergjini resides in France, and received his MBA from Fairleigh Dickinson University.


Element Global, Inc (OTC: ELGL), a diversified holding Company with global business interests centered on media and production, distribution and streaming in original and licensed film and tv content globally. With acquisition targets and developing sports franchise, sports distribution, emerging technology, renewable energy, and mining and processing of electric base metals, the Company brings together these enterprises to capitalize on both domestic and international opportunities. As new energy and smart digital technologies converge globally, supporting emissions reductions through the electrification of power, transport, industry and buildings, ELGL’s visions itself to capitalize on the increases in demand in these industries, www.elementglobal.com.


Safe Harbor Statement
Under the Private Securities Litigation Reform Act of 1995, certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

Element Acquisition Corporation Announces Formation of Investment Committee

Group of Leading Media, Entertainment and Sports Executives Will Oversee Investments Across These Sectors

LOS ANGELES, CA, June 4, 2020–Element Acquisition Corporation (“Element”), a wholly owned division of BioForce Nanosciences Holdings, Inc. (OTC: BFNH), announces that it has created an Investment Committee comprised of leading executives with extensive experience in the media, entertainment and sports sectors.

The Investment Committee will oversee a strategy aimed at acquiring and investing in companies across these industries, and Element will serve as an acquisition vehicle for these transactions.

“We see significant investment opportunities in media, entertainment and sports and are excited to come together to build a new company spanning these dynamic industries,” said Investment Committee member and Co-CEO of Element Acquisition Corporation, John LaViolette. “Based on this shared vision, the other committee members and I plan to leverage our deep relationships and experience to identify compelling targets to partially or fully acquire, and we plan to announce a number of transactions in the coming weeks.”

The members of the Investment Committee are:

  • John LaViolette – Mr. LaViolette is the Co-Founder and Co-CEO of Element International Inc, and Co-CEO and Director of Element Global, Inc. (OTC: ELGL). Mr. LaViolette was also a senior partner in the entertainment law firm of Bloom, Hergott, Diemer, Rosenthal, LaViolette, Feldman, Schenkman & Goodman LLP. He has deep relationships with all major Hollywood studios and networks and has represented a vast number of “A-list” actors, writers, and directors.
  • Steven Gagnon – Mr. Gagnon is the Co-Founder and Co-CEO of Element International Inc., and Co-CEO and COO of Element Global, Inc. (OTC: ELGL). Mr. Gagnon has a 20-year history in media in the financing and production of film, television and music videos. Mr. Gagnon served as President of the sports group of Madison Sports and Entertainment Group, Inc., and worked as a supervisor in the offshore oil and construction industry for International Underwater Contractors.
  • Sasha Shapiro – Mr. Shapiro is President and Director of Element Global, Inc. (OTC: ELGL) and Vice Chairman and President of Element Media Group. Mr. Shapiro is Managing Director of Media Content Capital, a private equity fund focused on investments in early/medium-stage media, internet, and entertainment companies. He has held senior management positions at Warner Bros Studios and Pacifica Ventures and has served as a producer on films including Fury, Sabotage, Fading Gigolo, Dirty Grandpa, Rock the Kasbah, Naked and Ophelia. He sits on the Board of Directors of Sonifi Solutions, QED International, Covert Media and VR MediaTech.
  • Mark Greenberg – Mr. Greenberg is CEO of Element Media Group Inc., and Director of Element Global, Inc. (OTC: ELGL). He served as the Founder and Chief Executive Officer of EPIX from 2009 to 2017 and was previously Executive Vice President for Showtime Networks, Inc., and Director of Direct Marketing at HBO (Home Box Office).
  • Neil Davis – Mr. Davis is the Chief Business Development Officer in Element Media Group. Mr. Davis is a seasoned digital executive who has created well over $2 billion of revenue for various companies including, AOL, Blockbuster, Dish Network and Qello Media, where he served as Chief Business Officer. He was previously CEO at Monetize, where he consulted for the media and entertainment industries. Prior to that, he was Head of Corporate and Digital Development at Blockbuster-Dish Digital.
  • Steve Scheffer — Mr. Scheffer has served almost 30 years at HBO (Home Box Office) as President of Film Programming, Video and Enterprises. Mr. Scheffer was responsible for overseeing all motion picture programming for HBO. As President of HBO Pictures, he was responsible for the financing and production of HBO’s Silver Screen Partners and Cinema Plus theatrical movie ventures. Prior to HBO, Mr. Scheffer held executive positions at Time Life Films, Allied Artists, Polydor Records, MGM and Columbia Pictures.

About Element Acquisition Corp.

Element Acquisition Corp. is a well-capitalized entity formed to pursue acquisitions in the media, entertainment, media technology and sports sectors. It was founded in 2020.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical Cord Mesenchymal Stem Cells

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) – Predictive Biotech, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19).

The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit. Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.

“Coronavirus can be deadly, in large part because the virus can cause ‘cytokine storms’ in which the patient’s own immune system triggers a runaway response causing more damage to the patient, than to the virus it’s trying to eliminate” said John Sorrentino, Chairman of Predictive Technology Group.  “Respiratory distress kills hundreds of thousands of people each year worldwide. There is clinical data from early clinical trials that seem to indicate that the avoidance of the cytokine storm utilizing MSCs may be a critical component for the treatment of COVID-19 infected patients.”

A recent review article published in Pain Physician, concluded that, “The limited but emerging evidence regarding UC MSC [umbilical cord mesenchymal stem cells] in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.”

The proposed IND clinical trial will utilize Predictive’s proprietary core technology of naturally occurring MSCs derived from umbilical cord tissue (UC-MSCs) to assess the efficacy as an add-on therapy to standard treatment of patients with severe Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19.

Predictive’s UC MSC product, CoreCyteTM,

has already been used as an allograft in over 50,000 patients.  Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration. No serious adverse events have been reported with CoreCyte regardless of the route of administration. If Predictive’s EUA request is approved, CoreCyte would be available immediately to critically ill patients with ARDS due to COVID-19 infections.  

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit www.predtechgroup.com.

About Predictive Biotech, Inc.

Predictive Biotech is a leader in regenerative medicine, its products are derived from tissue sources rich in properties that support the body’s natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Predictive’s signature products are uniquely born from the Wharton’s jelly layer of the umbilical cord and amniotic fluid and tissue.With over 100,000 units delivered, product safety and consistency has been realized by thousands of practices throughout the United States. A national network of clinics, health systems, researchers and physicians leverage Predictive’s four proprietary products: AmnioCyte™, AmnioCyte Plus™, PolyCyte™, and CoreCyte™.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks The Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect The Company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect The Company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by The Company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive Biotech

Info@predictivebiotech.com

888-407-9761

Predictive Technology Group Announces Initial Order of One Million Units of the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test from Distribution Partner, Wellgistics, LLC.

SALT LAKE CITY, April 8, 2020 (GLOBE NEWSWIRE) – Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), today shared that its distribution partner, Wellgistics, has submitted an initial order for immediate delivery of one (1) million units of the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test(Assurance AB)intended for use by laboratories and healthcare workers at the point-of-care in the U.S.

“We have been working diligently with Wellgistics to get this first order put in motion, even prior to making our partnership announcement on April 3,” said Bradley Robinson, CEO of Predictive Technology Group. “This country is in high need of the Assurance AB testing for point of care use and we have brought all resources to bear to bring this product to the United States. Wellgistics has provided us with state-by-state demand guidance, to ensure that regions with the most urgent need have first access to the test. Our main priorities will be to focus on servicing those areas,” Robinson continued.

“When our partnership with Predictive was announced last week, our team was very aware of the coming tsunami wave of interest for this test,” said Brian Norton, CEO of Wellgistics. “This demand grows each day as more attention hits the media and is recognized as a viable solution toward identifying immunity and allowing people to go back to work. Presently, the Wellgistics team is hyper focused on closing the final gaps of the complex web of international logistics. We feel great about where we are, and we will provide new updates as quickly as they are available.”

Predictive announced website updates relating to Assurance AB including:

Instructions For Use, Quick Reference Guide and Fact Sheet for laboratories and healthcare workers at the point-of-care. The website also includes an instructional video on administering the Assurance AB test. 

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit www.predtechgroup.com.

About Predictive Laboratories, Inc.

Predictive Laboratories’ molecular and genetic diagnostics focus on hard-to-diagnose and hard-to-detect diseases. Leveraging its vast genetic library, Predictive offers earlier detection of a variety of diseases through genetic assessments to guide personalized precision medicine.

Equipped with a state-of-the-art CAP and CLIA accredited laboratory, Predictive operations perform next-generation sequencing experiments, including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies. Predictive arms physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients. For more information, visit www.predictivelabs.com.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive Laboratories

Info@predictivelabs.com

855-497-3636

Predictive Technology Group Announces Distribution Agreement with Wellgistics, LLC for Its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test for Use by Laboratories and Healthcare Workers at the Point-of-Care

SALT LAKE CITY, April 2, 2020 — Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, today announced a distribution agreement between its subsidiary, Predictive Laboratories and Wellgistics, LLC of Lakeland, Florida for distribution in the U.S. of its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) intended for use by laboratories and healthcare workers at the point-of-care in the U.S.

Wellgistics, LLC, is one of the fastest growing wholesale pharmaceutical distributors in the United States. It is a logistics leader in the complex healthcare supply chain. Wellgistics is licensed in all 50 states as a Pharmaceutical Wholesale Distributor and is also licensed or permitted as Third-Party Logistics provider in all states. Its distribution facility, located in Lakeland, FL, is VAWD- accredited by the National Association of Boards of Pharmacy.

“From the onset of this global crisis, the Wellgistics’ leadership team has placed its sole focus on finding solutions for America.  We felt confident that our competency in healthcare and pharmaceutical distribution would be sought out by product innovators to assist in delivering critically needed supplies throughout the country.” Said Brian Norton, CEO of Wellgistics.

“Our newly established alliance with Predictive Laboratories allows us to leverage our complex distribution network in delivering the life-saving Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test to healthcare professionals all across the country. We are keenly aware and very impressed with the extensive steps taken by Predictive to ensure the highest levels of quality in their dual channel IgM/IgG product, which we believe will become the “gold standard” in the marketplace,” said Norton.

“We are pleased to partner with Wellgistics. They are an ideal partner and are able to scale and serve the most critical needs in the face of this global pandemic. Wellgistics’ logistics, expertise and infrastructure has demonstrated the ability to efficiently move products from around the world to the U.S. market and was an important component in our decision to partner with them. We are in production in advance of Wellgistic’s purchase orders and will update stakeholders on details over the next few days,” said Bradley Robinson, CEO of Predictive Technology Group. “We will support Wellgistics, their team and customers with Predictive Laboratories’ full scientific, operational and service team members,” added Robinson.

About the Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test:

The Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test is a rapid test for the qualitative detection of IgM and IgG antibodies associated with the SARS-CoV-2 virus. Assurance AB is a single-use, self-contained test that provides results in 15 minutes, helping authorities, employers and healthcare workers make informed decisions to contain the spread of COVID-19.

Assurance AB is intended for individuals who display signs and symptoms of COVID-19, individuals who were exposed to someone infected with COVID-19, or individuals who want qualitative information about whether or not they have IgM or IgG antibodies. Assurance AB is for use by laboratories and healthcare workers at the point-of-care.

What is antibody testing?

Antibody assays have the ability to detect past infections and indicate probable immunity. Antibodies are long-lasting and may be detected in the bloodstream several years after infection. 

Assurance AB detects the presence of antibodies IgM and IgG, developed in response to the SARS-CoV-2 virus. The antibody and its relative levels may be used to indicate the stage of infection and estimate time since exposure to the virus for contact tracing.

  • IgM: develop EARLY after SARS-CoV-2 virus exposure
  • IgG: develop LATER after SARS-CoV-2 virus exposure; indicates long-term immunity

Assurance AB Benefits

  • Results in 15 minutes
  • Highly accurate (92% sensitivity (CI95% 89.4-95.7%); 100% specificity (CI95% 96.8-100%))
  • NO laboratory equipment required
  • NO specialized training required, easy-to-use
  • Reduces risk of spreading the virus to healthcare workers administering tests or technicians processing tests
  • Provides actionable information to all patients to help determine if a COVID-19 viral PCR test is needed
  • Provides insightful information for when it is safe for individuals to go back to work and resume normal activities of daily life
  • Test kits can be stored and used at room temperature
  • Antibody testing is improved over nasopharyngeal swab testing by the fact that antibodies are more uniformly present in blood sampling

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care.  The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictive’s tests and products empower clinicians to provide their patients with the highest level of care.  For more information, visit https://predtechgroup.com/

About Predictive Laboratories, Inc.

Predictive Laboratories’ molecular and genetic diagnostics focus on hard-to-diagnose and hard-to-detect diseases. Leveraging its vast genetic library, Predictive offers earlier detection of a variety of diseases through genetic assessments to guide personalized precision medicine.

Equipped with a state-of-the-art CAP and CLIA accredited laboratory, Predictive operations perform next-generation sequencing experiments, including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies. Predictive arms physicians with the most robust diagnostic tools to provide personalized precision treatment for their patients. For more information, visit www.predictivelabs.com

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive Laboratories

Info@predictivelabs.com

855-497-3636

Predictive Technology Group and Manufacturing Partners Provide Updates of Its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test for Use by Laboratories and Healthcare Workers at the Point of Care

Company provides formal response to misleading recently published short report

SALT LAKE CITY, March 30, 2020 — Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics, and its manufacturing partner, Jiangsu Dablood Pharmaceutical CO, Ltd. (Dablood), a partner entity of Da An Gene Co., Ltd., today made several updates and progress reports on its Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test(Assurance AB)intended for laboratories and healthcare workers at the point-of-care in the U.S.   

“An opinion piece critical of Predictive was posted online last week by individually unidentified author(s) who admitted they have taken a short position in shares of The Company,” said John Sorrentino, chairman of Predictive Technology Group. “We encourage every reader to do their own due diligence and review the documents posted today on Predictive Laboratories’ website. The author(s), hiding behind anonymity – and attempts to disclaim – also warn that ‘Hindenburg Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information.’ Because the opinion piece itself warns readers of its short position-based bias and its unwillingness to guarantee the accuracy of any ‘information’ it espouses, The Company will not dignify the opinion piece with a point-by-point response, however we felt compelled to address a few egregious misrepresentations and untruths.”

The opinion piece asserts a material falsehood that “Dablood is NOT one of the companies approved by the Chinese government to offer COVID-19 tests. The official list of approved COVID-19 test providers is published by the Chinese government, was updated as of March 17th, and does not include Dablood or its affiliates.” If properly investigated, one can find that #5 on the referenced list is Da An Gene Co., Ltd. Guangzhou Darui Biotechnology, a subsidiary of Da An Gene Co., Ltd., has joint venture entity in Dablood. As such, Dablood operates under the Da An Gene Co., Ltd. license.

Regarding Predictive’s formal request for Emergency Use Authorization (EUA) from the FDA to distribute Assurance AB, the opinion piece states, in part, that “Predictive has no specific approval from requisite U.S. authorities to provide this test.” The Company views this statement as simply not true. 

“The FDA’s recent guidance on COVID-19 antibody (i.e. serological) diagnostic tests clearly allows manufacturers to market these tests in the United States to laboratories and healthcare workers at the point of care, so long as the tests have been validated and notification is provided to the FDA,” said Bradley Robinson, CEO of Predictive Technology Group. “The Predictive/Dablood test meets these criteria. Additionally, The Company has formally submitted an EUA with the FDA. If granted, this would provide Predictive the ability to market the test for in-home use.”

Predictive Laboratories, Inc., a wholly-owned entity of The Company, operates a CLIA-certified and CAP-accredited laboratory which is responsible for the distribution of the Assurance AB.Predictive Laboratories has updated its website to include the following:

  • Dablood Board of Directors response to the erroneous and misleading Hindenburg opinion piece published on March 27, 2020
  • FDA confirmation receipt of EUA application
  • Representative of Foreign Manufacturer Notice from Dablood to the FDA
  • Manufacturer FDA EUA Notification from Dablood to the FDA
  • U.S. Agent Retainer Agreement

“The Hindenburg piece repeatedly and inaccurately attempts to cast Predictive solely as a stem cell company while ignoring The Company’s other diagnostic assets, such as ARTguideTM and FertilityDXTM, and its recently announced diagnostic assay collaboration with Atrin Pharmaceuticals. In this context, a COVID-19 rapid antibody test is a logical addition to Predictive’s portfolio. Nevertheless, they attempt to cast Predictive as simply a stem cell company,” said Robinson. “Predictive encourages thoughtful investors to consider the motives of these anonymous authors when assessing the truthfulness and accuracy of any statement or report in the opinion piece. Predictive will pursue any and all legal actions against individuals and entities who intentionally mislead Predictive stakeholders.”

“The response to the announcement of Assurance AB (March 25, 2020) has been very strong,” continued Robinson. “In particular, both international and domestic governmental agencies have expressed strong interest in how rapid antibody testing can help with the public health response to this critical pandemic. We want to acknowledge the tireless activities by our employees and partners in developing a tool that can be a part of solving this global health crisis.”

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care.  The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care.  Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics.  For more information, visit https://predtechgroup.com.

About Predictive Laboratories, Inc.

Predictive Laboratories a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for any next-generation sequencing experiments including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies – www.predtechlabs.com.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

www.predictivelabs.com

Contacts:

Predictive Laboratories

institutional@predictivelabs.com

commercial@predictivelabs.com

info@predictivelabs.com

855-497-3636

Predictive Technology Group Announces Launch of Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test for Use by Laboratories and Healthcare Workers at the Point of Care

Assurance AB™ is a single-use, self-contained SARS-CoV-2 (COVID-19) antibody detection test that provides results in 15-minutes

SALT LAKE CITY, March 25, 2020 — Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in the development of genetic and molecular diagnostics and companion therapeutics today announced that in response to the demand for high volume test availability for the SARS-CoV-2 (COVID-19) global pandemic, Predictive Laboratories, a wholly-owned subsidiary of The Company has notified the U.S. Food and Drug Administration of its intent to immediately distribute the validated Assurance AB™ COVID-19 IgM/IgG Rapid Antibody Test (Assurance AB) test to laboratories and healthcare workers at the point-of-care in the U.S.  

The Assurance AB test was developed to detect the presence of IgM and/or IgG antibodies to the SARS-CoV-2 virus. The test requires only a fingerstick to sample an individual’s blood which is then placed on the self-contained test device. The test takes 15-minutes to display results. The test results indicate the presence of antibodies associated with the SARS-CoV-2 virus.

“Our company is committed to help with the global challenge of testing for the COVID-19 virus.” said Bradley Robinson, CEO of Predictive Technology Group. “Testing strategies for the pandemic are fluid and changing daily. We have worked diligently with our partners who have experience in testing tens of millions of patients worldwide. We appreciate their assistance in allocating resources and transferring vital knowledge for identifying individuals that have had an immune reaction and developed antibodies in response to virus exposure. Domestic and international governmental agencies, healthcare groups, pharmacies and employers have shown a strong interest in our test,” added Robinson. The Company will distribute the Assurance AB test through its wholly-owned subsidiary Predictive Laboratories, Inc., a CLIA certified and CAP accredited laboratory.

John Nelson M.D. former president of the American Medical Association and Predictive scientific advisory board member commented “The overwhelming need for a quick and accurate test for this pandemic is obvious. Focusing on an antibody test helps accelerate results and protect healthcare workers. The Assurance AB test is a valuable tool for truly understanding the spread of COVID-19 in the U.S.”

Assurance AB can help authorities, employers and healthcare workers make informed decisions on whether or not to continue precautions. Point of care serology testing may allow individuals with antibodies the confidence to go back to the workplace and engage in their communities.

Additional advantages of the Assurance AB test include:

  • inexpensive test with results in 15 minutes
  • antibody testing is less complex and remedies potential false negative results common in nasopharyngeal swab sampling
  • sample collection type (blood droplets) nearly eliminates the risk of spreading the virus to healthcare workers administering tests and/or to laboratory personnel who handle the submitted samples

Because of the rapid spread of the COVID-19 virus, several states including California and New York have recently expressed immediate need for rapid antibody testing. While there are benefits to viral testing, serology antibody testing allows patients to know if they have been exposed to the virus and if they have developed antibodies typically associated with immunity.

Assurance AB COVID-19 IgM/IgG Rapid Antibody Test is being manufactured in cooperation with Jiangsu Dablood Pharmaceutical CO, Ltd. Dablood Pharmaceutical has successfully distributed 38 million tests to date throughout Asia and Europe. To the best of Predictive’s knowledge, Dablood Pharmaceutical is one of very few companies approved by the Chinese government to co-develop and manufacture rapid antibody tests. Dablood Pharmaceutical is one of the largest diagnostic kit manufacturers in China and is currently producing up to 1.5 million units of the rapid antibody test per day in China. Predictive evaluated other potential developers and suppliers and believes Dablood Pharmaceutical provides not only existing inventory, its high-volume production capacity enables them to rapidly increase production to provide high-quality tests to meet rapidly expanding global demand. Dablood Pharmaceutical has been recognized by the Chinese government for its effort of developing and producing testing products to help the detect the COVID-19 and has received approval for distribution of its test across the domestic Chinese market and the European Union with a CE mark.

Predictive is also pursuing procurement authorization through the Biomedical Advance Research and Development Authority (BARDA) under the Office of the Assistant Secretary for Preparedness and Response (ASPR) in Health and Human Services (HHS). The Company cautions that if the federal government decides to restrict adequate reimbursement or the foreign import of products manufactured in Asia, the Company will not be able to provide access to these tests in the U.S.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care.  The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care.  Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics.  For more information, visit www.predtechgroup.com.

About Predictive Laboratories, Inc.

Predictive Laboratories a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) is focused on hard-to-detect diseases. The laboratory is equipped with state-of-the-art equipment for any next-generation sequencing experiments including whole exome sequencing, gene and genetic marker panels, and low-pass whole genome analysis of embryos for aneuploidies.

www.predictivelabs.com

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive Laboratories
institutional@predictivelabs.com
commercial@predictivelabs.com
info@predictivelabs.com
855-497-3636